Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 440Lung Neoplasms 170Neoplasms 31Adenocarcinoma of Lung 27Neoplasm Metastasis 23Breast Neoplasms 23Prostatic Neoplasms 19Squamous Cell Carcinoma of Head and Neck 17Small Cell Lung Carcinoma 17Colorectal Neoplasms 13Melanoma 12Stomach Neoplasms 11Adenocarcinoma, Bronchiolo-Alveolar 11Pancreatic Neoplasms 10Ovarian Neoplasms 10Carcinoma, Renal Cell 10Head and Neck Neoplasms 9Urinary Bladder Neoplasms 8Recurrence 8Esthesioneuroblastoma, Olfactory 8Carcinoma, Squamous Cell 8Salivary Gland Neoplasms 7Esophageal Neoplasms 7NSCLC 6Carcinoma 6Advanced Non-Small Cell Lung Cancer 6Sarcoma 5Pleural Effusion, Malignant 5Parkinson Disease 4, Autosomal Dominant Lewy Body 5Carcinoma, Transitional Cell 5

Interventions

famitinib 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Non Squamous Non Small Cell Lung × Docetaxel × Thoracic × Clear all
NCT02766140 2019-01-18

SHR1020 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Squamous Non Small Cell Lung Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Terminated
12 enrolled
Thoracic

Non Squamous Non Small Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡